Federal Register Notice: FDA has determined the regulatory review period for Retevase (reteplase) is 1,919 days for extending a patent which claims the human biological product. FDA approved Retevase for managing acute myocardial infarction (AMI) in adults for improving ventricular function following AMI, reducing incidence of congestive heart failure and reducing mortality associated with AMI. To view this notice, click here.
